Study volunteers had encouraging immune responses to the test.
One of the four experimental COVID-19 vaccines tested by Pfizer and its German partner BioNTech presented promising results when tested in 45 people.
According to the The Inquirer, via the Associated Press, “study volunteers given either a low or medium dose, in two shots about a month apart, had immune responses in the range expected to be protective, when compared to some COVID-19 survivors, according to the preliminary results.”
The Pfizer and BioNTech vaccine candidates make use of a piece of the coronavirus genetic code to “prime the body to recognise and attack the virus.” While the current testing operations is only at 45 people, Pfizer is intending to open a large-scale study. At the moment, around 15 COVID-19 vaccine candidates are being tested worldwide.
Various companies are studying and testing different types of vaccines, increasing the odds that at least one of the many approaches might work.
To read the original story, click here.
